跳至主要内容
临床试验/DRKS00015330
DRKS00015330尚未招募不适用

Cohort on Hepatitis C Micro-elimination in MSM - NOCO

Zibp GmbH0 个研究点目标入组 200 人开始时间: 2018年11月13日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
Male

入选标准

  • MSM with or without HIV with documented current or spontaneously cleared hepatitis C infection as defined below:
  • a. Documented HCV antibody seroconversion OR
  • b. HCV RNA positive AND
  • c. Prior negative anti-HCV antibody or HCV RNA test within 12 months OR
  • d. rise of any liver transaminases above ULN within the past 12 months with prior normal transaminases during the year before OR
  • e. any ALT elevation and suspected infectious event AND
  • f. exclusion of other causes of acute hepatitis or HCV reinfection after cured or cleared prior HCV infection, defined by
  • a. HCV RNA detectable after SVR12 or spontaneous clearance (two negative HCV RNA measures with an interval of 24 weeks) or
  • b. HCV genotype switch within these timeframes (s.above) and/or
  • c. HCV RNA detectable with phylogenetic proof of reinfection

排除标准

  • 1. Patients in whom a time-point of HCV infection cannot be estimated (midpoint between first positive and last negative HCV antibody or RNA (whichever more recent), midpoint between last normal and first raised ALT)
  • 2. Inability to provide written informed consent
  • 3. Younger than 18 years of age

研究者

发起方
Zibp GmbH

相似试验